R. Navarro

Effects of erythropoietin (rHuEpo) plus granulocyte colony stimulating factor (rHuG-CSF) for the treatment of myelodysplastic syndromes (MDS) on anemia, costs and quality of life: a randomized controlled trial.

A. Stamatoullas, A. Vekhoff, P. Durieux, 2004 .

Rituximab-Induced Vasculitis

J. Rossi, J. Guilhou, O. Dereure, 2001, Dermatology.

Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial

E. Solary, S. Chevret, E. Wattel, 2020 .

Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma

B. Klein, J. Moreaux, G. Cartron, 2015, Blood Cancer Journal.

Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network

A. Stamatoullas, K. Götze, E. Solary, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II, single‐arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B‐cell lymphoma

R. Houot, B. Coiffier, R. Bouabdallah, 2016, British journal of haematology.

Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial.

H. Dombret, A. Stamatoullas, A. Vekhoff, 2004, Blood.

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects

B. Klein, M. Bozonnat, J. Widjenes, 2005, Bone Marrow Transplantation.